-
1
-
-
79959795786
-
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
-
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-16.
-
(2011)
N Engl J Med
, vol.364
, pp. 2507-2516
-
-
Chapman, P.B.1
Hauschild, A.2
Robert, C.3
Haanen, J.B.4
Ascierto, P.5
Larkin, J.6
-
2
-
-
77957089182
-
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
-
Joseph EW, Pratilas CA, Poulikakos PI, Tadi M, Wang W, Taylor BS, et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A 2010; 107: 14903-8.
-
(2010)
Proc Natl Acad Sci U S A
, vol.107
, pp. 14903-14908
-
-
Joseph, E.W.1
Pratilas, C.A.2
Poulikakos, P.I.3
Tadi, M.4
Wang, W.5
Taylor, B.S.6
-
3
-
-
77949732073
-
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wildtype BRAF
-
Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wildtype BRAF. Nature 2010; 464: 427-30.
-
(2010)
Nature
, vol.464
, pp. 427-430
-
-
Poulikakos, P.I.1
Zhang, C.2
Bollag, G.3
Shokat, K.M.4
Rosen, N.5
-
4
-
-
83455254767
-
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
-
Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011; 480: 387-90.
-
(2011)
Nature
, vol.480
, pp. 387-390
-
-
Poulikakos, P.I.1
Persaud, Y.2
Janakiraman, M.3
Kong, X.4
Ng, C.5
Moriceau, G.6
-
5
-
-
84875717480
-
A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition
-
Whittaker SR, Theurillat JP, Van Allen E, Wagle N, Hsiao J, Cowley GS, et al. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov 2013; 3: 350-62.
-
(2013)
Cancer Discov
, vol.3
, pp. 350-362
-
-
Whittaker, S.R.1
Theurillat, J.P.2
van Allen, E.3
Wagle, N.4
Hsiao, J.5
Cowley, G.S.6
-
6
-
-
80051625929
-
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling
-
Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 2011; 29: 3085-96.
-
(2011)
J Clin Oncol
, vol.29
, pp. 3085-3096
-
-
Wagle, N.1
Emery, C.2
Berger, M.F.3
Davis, M.J.4
Sawyer, A.5
Pochanard, P.6
-
7
-
-
84856217925
-
Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF
-
Xing F, Persaud Y, Pratilas CA, Taylor BS, Janakiraman M, She QB, et al. Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene 2012; 31: 446-57.
-
(2012)
Oncogene
, vol.31
, pp. 446-457
-
-
Xing, F.1
Persaud, Y.2
Pratilas, C.A.3
Taylor, B.S.4
Janakiraman, M.5
She, Q.B.6
-
8
-
-
84869067183
-
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas
-
Lito P, Pratilas CA, Joseph EW, Tadi M, Halilovic E, Zubrowski M, et al. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 2012; 22: 668-82.
-
(2012)
Cancer Cell
, vol.22
, pp. 668-682
-
-
Lito, P.1
Pratilas, C.A.2
Joseph, E.W.3
Tadi, M.4
Halilovic, E.5
Zubrowski, M.6
-
9
-
-
84861863158
-
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib
-
Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2012; 2: 227-35.
-
(2012)
Cancer Discov
, vol.2
, pp. 227-235
-
-
Corcoran, R.B.1
Ebi, H.2
Turke, A.B.3
Coffee, E.M.4
Nishino, M.5
Cogdill, A.P.6
-
10
-
-
84868224906
-
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
-
Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367: 1694-703.
-
(2012)
N Engl J Med
, vol.367
, pp. 1694-1703
-
-
Flaherty, K.T.1
Infante, J.R.2
Daud, A.3
Gonzalez, R.4
Kefford, R.F.5
Sosman, J.6
-
11
-
-
84880254869
-
Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors
-
Morris EJ, Jha S, Restaino CR, Dayananth P, Zhu H, Cooper A, et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov 2013;3:742-50.
-
(2013)
Cancer Discov
, vol.3
, pp. 742-750
-
-
Morris, E.J.1
Jha, S.2
Restaino, C.R.3
Dayananth, P.4
Zhu, H.5
Cooper, A.6
-
12
-
-
84873728334
-
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
-
Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 2013; 494: 251-5.
-
(2013)
Nature
, vol.494
, pp. 251-255
-
-
Das Thakur, M.1
Salangsang, F.2
Landman, A.S.3
Sellers, W.R.4
Pryer, N.K.5
Levesque, M.P.6
|